| Literature DB >> 33209049 |
Jiajia Shi1, Ying Sun1, Jiajia Hua2.
Abstract
BACKGROUND: Stroke is a leading cause of death and disability worldwide. It remains difficult to treat brain injury and improve functional rehabilitation after cerebral ischemia. Brain-derived neurotrophic factor (BDNF) is involved in ischemic stroke (IS) through interactions in the CREB1-BDNF-NTRk2 pathway. In this study, we aimed to determine the association of NTRK2 gene polymorphisms and the effects of intergenetic interactions in the Chinese population.Entities:
Keywords: NTRK2; bioinformatics; homocysteine; ischemic stroke; miRNA
Year: 2020 PMID: 33209049 PMCID: PMC7669521 DOI: 10.2147/PGPM.S270319
Source DB: PubMed Journal: Pharmgenomics Pers Med ISSN: 1178-7066
Clinical Characteristics of Ischemic Stroke Patients and Healthy Controls
| Characteristics | Cases (n=400) | Control (n=400) | |
|---|---|---|---|
| Age | >0.05 | ||
| >60 | 349 | 351 | |
| <60 | 51 | 49 | |
| Gender | >0.05 | ||
| Male | 276 | 244 | |
| Female | 124 | 156 | |
| Smoking exposure | <0.001 | ||
| Yes | 301 | 181 | |
| No | 99 | 219 | |
| Drinking exposure | <0.001 | ||
| Yes | 279 | 199 | |
| No | 121 | 201 | |
| Diabetes | 0.007 | ||
| Yes | 241 | 203 | |
| No | 159 | 197 | |
| Hypertension | <0.001 | ||
| Yes | 311 | 129 | |
| No | 89 | 271 | |
| Total cholesterol(mmol/L) | 4.88(4.11–5.14) | 4.79(4.12–5.13) | >0.05 |
| HDL-C(mmol/L) | 0.87(0.44–1.71) | 1.52(1.08–1.87) | <0.001 |
| LDL-C(mmol/L) | 4.99 (4.11–6.21) | 2.83(1.77–3.31) | <0.001 |
Note: aStudent t-test for continuous variable, Chi-squared test for categorical variable
Genotype Frequencies of the NTRK2 Polymorphisms in is Patients and Healthy Controls
| Genotype | Cases (n =400) | Controls (n = 400) | OR | |||
|---|---|---|---|---|---|---|
| N | % | N | % | |||
| rs11140793 | ||||||
| AA | 322 | 80.5 | 331 | 82.7 | 1.00 | |
| AC | 53 | 13.3 | 51 | 12.7 | 1.68 (0.83–1.87) | 0.03 |
| CC | 25 | 6.2 | 18 | 4.6 | 1.79 (0.91–1.99) | 0.01 |
| rs7047042 | ||||||
| CC | 371 | 92.7 | 382 | 95.5 | 1.00 | |
| CG | 23 | 5.8 | 16 | 4 | 1.12 (1.01–1.65) | 0.02 |
| GG | 6 | 1.5 | 2 | 0.5 | 1.31 (1.08–1.78) | 0.02 |
| rs1221 | ||||||
| CC | 344 | 86.0 | 351 | 87.7 | 1.00 | |
| CT | 38 | 9.5 | 37 | 9.3 | 1.33 (1.19–2.33) | 0.01 |
| TT | 18 | 4.5 | 12 | 3 | 1.41 (1.21–2.45) | 0.005 |
Note: aThe ORs, 95% CIs and P value were calculated after adjusting for smoking, drinking and other characteristics listed in Table 1.
Figure 1The function miRNAs associated with NTRK2 polymorphisms. (A): Relative expression of NTRK2 mRNA in patients with different genotypes of IS. (B): Luciferase of rs11140793 was detected by miRNA. (C): Luciferase of rs7047042 was detected by miRNA. (D): Luciferase of rs1221 was detected by miRNA. 293T cells were co-transfected with miRNAs simulator or control Renilla luciferase vector PRL-SV40 for 48 h. Luciferase activity in fireflies and renal cells was determined using the luciferase assay kit. The luciferase firefly signal was normalized to the renal luciferase signal. Data are expressed as mean ± standard deviation. *P < 0.05.
Candidate miRNAs Associated with NTRK2 Polymorphisms Predicted by Bioinformatics Analysis
| Gene | SNP | miRNA-ID | ΔG Binding (kCal/mol) |
|---|---|---|---|
| rs11140793 | hsa-miR-181a-3p | −15.32 | |
| hsa-miR-3181 | −14.60 | ||
| hsa-miR-3944-3p | −17.90 | ||
| hsa-4437 | −20.35 | ||
| hsa-4750-5p | −18.49 | ||
| hsa-6741-3p | −14.67 | ||
| rs7047042 | hsa-miR-127-5p | −9.01 | |
| hsa-miR-4786-3p | −14.83 | ||
| hsa-miR-7843-3p | −19.25 | ||
| rs1221 | hsa-4436b-5p | −18.36 | |
| hsa-miR-483-3p | −15.99 | ||
| hsa-miR-6509-3p | −13.95 | ||
| hsa-miR-6777-3p | −12.41 |
Note: ΔG binding (kCal/mol): binding energy based on ensemble free energy.
Clinical Outcome Correlation of NTRK2 Polymorphisms with is Patients
| Feature | Genotype (rs11140793) | AC vs AA* | CC vs AA* | ||
|---|---|---|---|---|---|
| AA | AC | CC | |||
| NIHSS ac (Mean/SD) | 3.1/1.1 | 4.2/1.5 | 4.8/1.1 | 0.02 | 0.005 |
| NIHSS 3m (Mean/SD) | 0.6/0.1 | 0.8/0.2 | 1.1/0.2 | 0.03 | |
| tHcy (mmol/L) | 12.3/1.8 | 13.5/1.5 | 15.5/1.4 | 0.01 | |
| 0.08/0.022 | 0.06/0.018 | 0.04/0.11 | 0.02 | ||
| NIHSS ac (Mean/SD) | 3.2/1.1 | 3.5/1.3 | 4.1/2.1 | 0.04 | 0.02 |
| NIHSS 3m (Mean/SD) | 0.7/0.1 | 0.9/0.2 | 1.0/0.2 | 0.03 | 0.01 |
| tHcy (mmol/L) | 11.8/1.9 | 12.1/1.6 | 14.2/1.8 | 0.01 | 0.04 |
| 0.09/0.012 | 0.06/0.021 | 0.04/0.19 | 0.02 | ||
| NIHSS ac (Mean/SD) | 3.5/1.1 | 3.6/1.7 | 4.2/2.1 | 0.12 | 0.03 |
| NIHSS 3m (Mean/SD) | 1.1/0.4 | 1.1/0.6 | 1.3/0.8 | 0.23 | 0.02 |
| tHcy (mmol/L) | 10.8/1.9 | 13.2/0.2 | 13.1/0.3 | 0.001 | 0.002 |
| 0.06/0.032 | 0.03/0.021 | 0.01/0.011 | 0.01 | 0.03 | |
Notes: *Student t-test for either genotype distributions or allele frequencies in IS patients. bRelative expression of NTRK2 normalized with GAPDH. NIHSS ac, initial stroke severity during the acute phase; NIHSS 3m, stroke severity after 3 months; MTHFR: Relative expression of MTHGR mRNA in IS patients.